|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||||||
| Current assets : | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Trade receivables | ||||||||||||||||||||
| Other current assets | ||||||||||||||||||||
| Total current assets | ||||||||||||||||||||
| Non-current assets | ||||||||||||||||||||
| Property, plant, and equipment, net | ||||||||||||||||||||
| Right-of-use assets | ||||||||||||||||||||
| Intangible assets | ||||||||||||||||||||
| Other non-current assets | ||||||||||||||||||||
| Total non-current assets | ||||||||||||||||||||
| Total Assets | ||||||||||||||||||||
| Liabilities and shareholders' equity | ||||||||||||||||||||
| Current liabilities: | ||||||||||||||||||||
| Trade payables | ||||||||||||||||||||
| Short-term operating leases' liabilities | ||||||||||||||||||||
| Short-term financial debt | ||||||||||||||||||||
| Current contingencies & Employee Benefits | ||||||||||||||||||||
| Other current liabilities | ||||||||||||||||||||
| Total current liabilities | ||||||||||||||||||||
| Non-current liabilities | ||||||||||||||||||||
| Long-term operating leases' liabilities | ||||||||||||||||||||
| Long-term financial debt | ||||||||||||||||||||
| Non-current contingencies & Employee Benefits | ||||||||||||||||||||
| Other non-current liabilities | ||||||||||||||||||||
| Total non-current liabilities | ||||||||||||||||||||
| Total Liabilities | ||||||||||||||||||||
| Shareholders’ equity : | ||||||||||||||||||||
| Ordinary shares, €0.10 par value; 296,061,497 and 235,670,864 shares authorized, and issued as of June 30, 2026 and December 31, 2025, respectively, | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Treasury stock 303,744, and 222,988 ordinary shares as of June 30, 2024 and December 31, 2023, respectively, at cost | ||||||||||||||||||||
| Treasury stock, 146,321 and 74,680 ordinary shares as of June 30, 2026 and December 31, 2025, respectively, at cost | ||||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||||
| Accumulated other comprehensive income | ||||||||||||||||||||
| Accumulated currency translation effect | ||||||||||||||||||||
| Total Shareholders’ equity | ||||||||||||||||||||
| Total Liabilities and Shareholder's equity |
Loading...
